What has been the main impact of MFN?

It is not bringing down US prices, but delaying launches in Europe. Reuters reports: Drug launches in EU markets fell by some 35% in the 10 months since Trump’s executive order, compared with the previous ​10 months…Delaying launches at lower EU prices could help secure higher U.S. prices for longer. You can read the full…

Read More

Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen?

Zenas Biopharma’s obexelimab achieved a statistically significant and clinically meaningful reduction in signs and symptoms of immunoglobulin G4-related disease, but not to the extent shown by Amgen’s Uplizna in its pivotal study. Still, Zenas points to features of its drug that could make it competitive as a maintenance therapy for the rare autoimmune disorder. The…

Read More

Andrea Ippolito, CEO, Simplifed

Andrea Ippolito has combined her personal experience as a mum struggling with breast feeding, and her professional career as an entrepreneur and engineer at Athenahealth building integrations with EMRs. She’s now the CEO of Simplifed which has built a network of lactation consultants, and much more, and has placed it in the workflow of that…

Read More